Immunocore Statistics
Share Statistics
Immunocore has 50.03M shares outstanding. The number of shares has increased by 0.6% in one year.
| Shares Outstanding | 50.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 48.66M |
| Failed to Deliver (FTD) Shares | 1.13K |
| FTD / Avg. Volume | 0.41% |
Short Selling Information
The latest short interest is 7.06M, so 14.11% of the outstanding shares have been sold short.
| Short Interest | 7.06M |
| Short % of Shares Out | 14.11% |
| Short % of Float | 14.5% |
| Short Ratio (days to cover) | 28.4 |
Valuation Ratios
The PE ratio is -60.41 and the forward PE ratio is -19.74.
| PE Ratio | -60.41 |
| Forward PE | -19.74 |
| PS Ratio | 13.39 |
| Forward PS | 4 |
| PB Ratio | 9.06 |
| P/FCF Ratio | -1344.1 |
| PEG Ratio | n/a |
Enterprise Valuation
Immunocore has an Enterprise Value (EV) of 3,340.20B.
| EV / Earnings | -60415.27 |
| EV / Sales | 13391.35 |
| EV / EBITDA | -64674.49 |
| EV / EBIT | -55997.23 |
| EV / FCF | -1344136.34 |
Financial Position
The company has a current ratio of 3.8, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.8 |
| Quick Ratio | 3.77 |
| Debt / Equity | 0.13 |
| Total Debt / Capitalization | 11.52 |
| Cash Flow / Debt | 0.06 |
| Interest Coverage | -11.57 |
Financial Efficiency
Return on equity (ROE) is -0.15% and return on capital (ROIC) is -11.96%.
| Return on Equity (ROE) | -0.15% |
| Return on Assets (ROA) | -0.09% |
| Return on Capital (ROIC) | -11.96% |
| Revenue Per Employee | 501.87K |
| Profits Per Employee | -111.24K |
| Employee Count | 497 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 0.23 |
Taxes
| Income Tax | -5.60M |
| Effective Tax Rate | 0.09 |
Stock Price Statistics
The stock price has increased by -55.09% in the last 52 weeks. The beta is 0.72, so Immunocore's price volatility has been higher than the market average.
| Beta | 0.72 |
| 52-Week Price Change | -55.09% |
| 50-Day Moving Average | 31.47 |
| 200-Day Moving Average | 40.32 |
| Relative Strength Index (RSI) | 47.47 |
| Average Volume (20 Days) | 277.89K |
Income Statement
In the last 12 months, Immunocore had revenue of 249.43M and earned -55.29M in profits. Earnings per share was -1.13.
| Revenue | 249.43M |
| Gross Profit | 248.39M |
| Operating Income | -59.65M |
| Net Income | -55.29M |
| EBITDA | -51.65M |
| EBIT | -59.65M |
| Earnings Per Share (EPS) | -1.13 |
Balance Sheet
The company has 442.63M in cash and 84.03M in debt, giving a net cash position of 358.59M.
| Cash & Cash Equivalents | 442.63M |
| Total Debt | 84.03M |
| Net Cash | 358.59M |
| Retained Earnings | -744.67M |
| Total Assets | 1.08B |
| Working Capital | 739.66M |
Cash Flow
In the last 12 months, operating cash flow was 2.94M and capital expenditures -5.42M, giving a free cash flow of -2.48M.
| Operating Cash Flow | 2.94M |
| Capital Expenditures | -5.42M |
| Free Cash Flow | -2.48M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 9.96K%, with operating and profit margins of -2.39K% and -2.22K%.
| Gross Margin | 9.96K% |
| Operating Margin | -2.39K% |
| Pretax Margin | -2.44K% |
| Profit Margin | -2.22K% |
| EBITDA Margin | -20.71% |
| EBIT Margin | -23.91% |
| FCF Margin | -1% |
Dividends & Yields
IMCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3.78% |
| FCF Yield | -0.17% |
Analyst Forecast
The average price target for IMCR is $66.5, which is 122.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $66.5 |
| Price Target Difference | 122.5% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Scores
| Altman Z-Score | 1.2 |
| Piotroski F-Score | 3 |